An Israeli-based company hopes to fill the void amid the ongoing baby-formula shortage in the United States.
Follow Israel Hayom on Facebook, Twitter, and Instagram
Three weeks ago, the US Food and Drug Administration issued emergency guidance enabling the import of infant formulas produced abroad. Tel Aviv-based health-tech company MyOr is among companies seeking FDA approval as its Mexican subsidiary, AlphaCare, produces and markets MyOr formulas from a plant in north-central Mexico.
"We have 200,000 cans of formula ready to be shipped right now, with a capacity to produce another 250,000 a month," said MyOr co-founder Michael Brandwein. Once it receives FDA approval, he said, the company can ship formula to homes and distributors in a matter of days, as many back-end arrangements have already been made.
Among the formula products AlphaCare makes are specialty ones in very short supply.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
"These are for premature babies and for infants dealing with food allergies and sensitivities," said Brandwein. "They are produced by fewer companies and in smaller batches."
He said the company remains hopeful that "approval will come in the next few days," describing the process as akin to the frantic early approval process for COVID-19 vaccines.
MyOr CEO Ariel Katz said the company has received "numerous requests from distressed retailers in the US eager to supply our products.
"We're talking about the most basic and humane act of providing newborn babies with nutrition," Katz said.
This article was first published by JNS.org.
